Premier Fund Managers Ltd Purchases Shares of 49,450 Johnson & Johnson (NYSE:JNJ)

Premier Fund Managers Ltd bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 49,450 shares of the company's stock, valued at approximately $7,982,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Innealta Capital LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth $27,000. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth about $31,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares in the last quarter. Morton Brown Family Wealth LLC boosted its holdings in shares of Johnson & Johnson by 400.0% in the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company's stock worth $41,000 after buying an additional 200 shares during the period. Finally, MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth approximately $43,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company's stock, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Guggenheim raised their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. Daiwa Capital Markets downgraded Johnson & Johnson from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Daiwa America lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 23rd. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $175.94.

Johnson & Johnson Stock Down 0.4 %

NYSE JNJ traded down $0.64 during trading on Wednesday, hitting $152.36. 3,547,483 shares of the company traded hands, compared to its average volume of 7,009,026. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The business has a fifty day simple moving average of $160.83 and a 200 day simple moving average of $156.19. The company has a market capitalization of $366.82 billion, a P/E ratio of 22.09, a PEG ratio of 2.74 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period in the previous year, the company earned $2.66 EPS. The company's revenue for the quarter was up 5.2% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.